ENDRA Life Sciences (NASDAQ:NDRA) Announces Earnings Results

ENDRA Life Sciences (NASDAQ:NDRA) announced its earnings results on Friday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.21, Zacks reports.

ENDRA Life Sciences Price Performance

NASDAQ NDRA opened at $4.47 on Friday. ENDRA Life Sciences has a 52 week low of $2.96 and a 52 week high of $9.85. The company has a 50 day moving average price of $4.85 and a 200 day moving average price of $4.60. The firm has a market cap of $5.68 million, a PE ratio of -0.70 and a beta of -0.05.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NDRA shares. Ascendiant Capital Markets reduced their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Weiss Ratings downgraded ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, ENDRA Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $25.00.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.